A prospective study of leukemic transformation control and hematopoietic recovery in patients with myelodysplastic syndrome(MDS) receiving iron chelation therapy with deferasirox(Exjade)

A prospective study of leukemic transformation control and hematopoietic recovery in patients with myelodysplastic syndrome(MDS) receiving iron chelation therapy with deferasirox(Exjade) - A prospective study of leukemic transformation control and hematopoietic recovery in patients with myelodysplastic syndrome(MDS) receiving iron chelation therapy with deferasirox(Exjade)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003365

Enrollment

Registered

2010-04-01

Start date

2010-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myelodysplastic syndome

Interventions

The patients with MDS are administered Deferasirox a once-daily dose of 5 mg/kg.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1, The iron overload patients (age 20-85) with MDS in WHO classification. 2, The Serum ferritin(SF) level is above the normal range.

Exclusion criteria

Exclusion criteria: 1, heavy renal and liver disorder. 2, during pregnancy, the lactation period. 3, allergy to Deferasirox 4, The case who cannot receive informed consent from patients. 5, The patients who received chemotherapy, except for oral chemoterapy.

Design outcomes

Primary

Measure	Time frame
The marker about iron overload once three months. Bone marrow aspiration after one year.	—

Countries

Japan

Contacts

Public ContactTakashi Maeda

Showa University School of Medicine Division of Hematology, Department of Medicine

03-3784-8338

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026